GU Cancers 2024 | SWOG 1605: predicting EFS with genomic profiling in NMBIC

Marie-Pier St-Laurent, MD, University of British Columbia, Vancouver, Canada, discusses findings from the Phase II SWOG 1605 trial (NCT02844816), which investigated the efficacy of urinary comprehensive genomic profiling (uCGP) in predicting event-free survival (EFS) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) treated with atezolizumab. The study, utilizing the UroAmp platform, analyzed genomic patterns at baseline and after four cycles of treatment. High-risk uCGP scores were associated with increased risks of high-grade recurrence, and the results suggest the potential of uCGP to identify patients at higher risk, aiding in treatment decisions and possibly guiding early treatment intensification. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.